Rallybio Co. (NASDAQ:RLYB) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Rallybio Co. (NASDAQ:RLYBGet Free Report) has received an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $12.20.

A number of analysts have recently issued reports on the stock. Wedbush cut their price target on shares of Rallybio from $13.00 to $11.00 and set an “outperform” rating for the company in a report on Thursday, April 11th. JPMorgan Chase & Co. downgraded Rallybio from an “overweight” rating to a “neutral” rating in a research report on Wednesday, May 15th. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Rallybio in a research report on Friday, May 10th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 target price on shares of Rallybio in a research report on Thursday, April 18th.

View Our Latest Report on RLYB

Hedge Funds Weigh In On Rallybio

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. abrdn plc purchased a new stake in Rallybio during the fourth quarter worth about $4,128,000. SG Americas Securities LLC purchased a new stake in Rallybio during the 4th quarter worth approximately $40,000. Vanguard Group Inc. increased its stake in Rallybio by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 1,076,771 shares of the company’s stock worth $1,992,000 after buying an additional 12,801 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in Rallybio during the 1st quarter worth approximately $57,000. 90.34% of the stock is currently owned by hedge funds and other institutional investors.

Rallybio Stock Up 2.3 %

Shares of NASDAQ:RLYB opened at $1.32 on Friday. Rallybio has a 52-week low of $1.16 and a 52-week high of $6.38. The stock has a market cap of $54.71 million, a P/E ratio of -0.70 and a beta of -1.69. The business has a fifty day moving average of $1.57 and a two-hundred day moving average of $1.73.

Rallybio (NASDAQ:RLYBGet Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.03. On average, equities analysts anticipate that Rallybio will post -1.42 earnings per share for the current year.

Rallybio Company Profile

(Get Free Report

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.

Recommended Stories

Analyst Recommendations for Rallybio (NASDAQ:RLYB)

Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.